SHANGHAI HENLIUS BIOTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.5 HKD | +0.98% |
|
+11.34% | +18.71% |
| 08:55am | Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA | MT |
| Apr. 24 | Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China | MT |
| Sales 2024 * | 5.89B 813M 6.37B | Sales 2025 * | 6.46B 891M 6.98B | Capitalization | 8.22B 1.13B 8.88B |
|---|---|---|---|---|---|
| Net income 2024 * | 600M 82.8M 648M | Net income 2025 * | 713M 98.39M 770M | EV / Sales 2024 * | 1.39 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.27 x |
| P/E ratio 2024 * |
13.5
x | P/E ratio 2025 * |
11.4
x | Employees | 3,637 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 15.03% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.98% | ||
| 1 week | +11.34% | ||
| Current month | +21.15% | ||
| 1 month | +18.19% | ||
| 3 months | +17.02% | ||
| 6 months | +43.98% | ||
| Current year | +18.71% |
1 week
14.70
16.50
1 month
13.6016.50
Current year
12.2016.50
1 year
9.6016.50
3 years
9.6046.20
5 years
9.6067.05
10 years
9.6067.05
| Managers | Title | Age | Since |
|---|---|---|---|
Wei Dong Jiang
FOU | Founder | - | 09-11-30 |
Jun Zhu
CEO | Chief Executive Officer | 46 | 21-11-29 |
Wei Huang
PSD | President | 56 | 20-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qi Yu Chen
BRD | Director/Board Member | 52 | 13-01-14 |
Tak Young So
BRD | Director/Board Member | 54 | 19-09-01 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | 18-12-23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 2 M€ | -.--% | ||
| 0.01% | 7 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 16.5 | +0.98% | 594 000 |
| 24-04-25 | 16.34 | +4.08% | 466,100 |
| 24-04-24 | 15.7 | +2.88% | 583,600 |
| 24-04-23 | 15.26 | 0.00% | 419,700 |
| 24-04-22 | 15.26 | +2.97% | 749,000 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am EDT
More quotes
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Companyâs main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
Sector
Pharmaceuticals
Calendar
2024-05-20
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
15.12
CNY
Average target price
16.39
CNY
Spread / Average Target
+8.37%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +18.71% | 1.13B | |
| -4.66% | 87.53B | |
| +2.63% | 40.42B | |
| -21.76% | 29.48B | |
| +55.39% | 25.43B | |
| -14.78% | 15.59B | |
| -18.49% | 11.49B | |
| -15.61% | 11.1B | |
| -44.02% | 11.3B | |
| +4.49% | 8.75B |
- Stock Market
- Equities
- 2696 Stock
